Metabolic cytometry for in-line process analysis

用于在线过程分析的代谢细胞术

• 批准号: 10698665
• 负责人: Jesung Park
• 金额: $ 28.62万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-15 至 2025-03-14
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10698665
• 关键词: 3-Dimensional; Acceleration; Anabolism; Biological Products; Biological Response Modifier Therapy; Biomanufacturing; Bioreactors; Cell Culture Techniques; Cell Extracts; Cell Line; Cell Proliferation; Cell physiology; Cells; Cellular Morphology; Clinical; Collaborations; Collection; Complex; Cytometry; Data; Development; Disease; Embryo; Evaluation; Fiber; Flavin-Adenine Dinucleotide; Fluorescence; Future; Gene Delivery; Gene Transduction Agent; Genes; Goals; Government; Growth; Harvest; Hereditary Disease; Human; Individual; Infection; Investigation; Investments; Kidney; Life Expectancy; Light; Mammalian Cell; Massachusetts; Measurement; Measures; Metabolic; Metabolism; Methodology; Monitor; Nicotinamide adenine dinucleotide; Noise; Optics; Organism; Oxidation-Reduction; Pathway interactions; Patients; Performance; Persons; Pharmaceutical Preparations; Phase; Process; Production; Productivity; Research; Resolution; Sampling; Signal Transduction; Specificity; Spectrum Analysis; Suspension Culture; System; Techniques; Technology; Therapeutic; Time; Universities; Validation; Viral; Viral Vector; bioprocess; commercialization; design; fluorophore; gene product; gene therapy; improved; inhibitor; innovation; instrument; large scale production; manufacture; manufacturing capabilities; medical schools; metabolomics; miniaturize; novel; operation; physical science; prevent; programs; promoter; prototype; sensor; success; technology development; temporal measurement; therapeutic gene; tool; virology

Project Summary/Abstract Gene therapy uses genes to prevent and/or treat acquired disorders and inherited genetic diseases. Recently, the intensive investigation of human genes and related diseases has improved the capability of gene therapy as a promising future therapy that can significantly increase life expectancy for millions of patients suffering from incurable diseases. This promise has accelerated the exponential growth in the field of gene therapy. However, the clinical potential of gene therapy remains largely unleashed, mainly due to the limited biomanufacturing capacity of gene delivery products for clinical and commercial use. Manufacturing of gene therapeutic biologics involves harvesting viral vectors in mammalian cell cultures which are highly complex and difficult to control. The lack of understanding and control of the viral production processes has led to manufacturing challenges including low productivity, instability of cell lines, high levels of impurities, and difficult scalability with consistent product quality. Therefore, new biomanufacturing analytical technologies are critically needed to improve the understanding of the bioprocess dynamics and to support development of robust and efficient biomanufacturing processes. Physical Sciences Inc. (PSI), in collaboration with the University of Massachusetts Lowell (UML) proposes to develop a novel biomanufacturing process analytical technology tool that enables in-line, continuous measurement of the metabolism of host cells in bioreactors for the large-scale manufacturing of therapeutic viral vectors. A novel metabolic cytometry sensor probe that measures the autofluorescence of intracellular metabolites will be used for real-time assessment of cellular-level redox metabolic state. An innovative spatially and temporally confined spectroscopy approach is used to efficiently differentiate fluorescence signals of intracellular metabolites from the nonspecific light background, achieving high specificity measurement of cellular physiology. During the Phase I program, a prototype fiber-based fluorescence cytometry probe system will be fabricated and evaluated, demonstrating the capability of the real-time metabolic measurement during bioreactor operations for viral vector production. Technology maturation and application demonstrations in additional bioreactors using a variety of culture organisms will be performed during the Phase II program. Successful development of this technology will contribute to significant improvement in the understanding and control of bioprocesses for large-scale manufacturing of viral vector products for gene therapy.

项目总结/摘要 基因疗法使用基因来预防和/或治疗获得性疾病和遗传性遗传疾病。 近年来，对人类基因和相关疾病的深入研究提高了基因诊断的能力， 治疗作为一种有前途的未来疗法，可以显着增加数百万患者的预期寿命 患有不治之症这一前景加速了基因领域的指数增长 疗法然而，基因治疗的临床潜力仍然在很大程度上释放，主要是由于有限的 用于临床和商业用途的基因递送产品的生物制造能力。基因制造 治疗性生物制剂涉及在哺乳动物细胞培养物中收获病毒载体， 很难控制对病毒生产过程缺乏了解和控制， 制造挑战包括生产率低、细胞系不稳定、杂质水平高，以及 难以实现可扩展性和一致的产品质量。因此，新的生物制造分析技术 是迫切需要的，以提高对生物过程动力学的理解，并支持发展 强大而高效的生物制造工艺。 物理科学公司(PSI)，与马萨诸塞州洛厄尔大学（UML）合作，提出 开发一种新型的生物制造过程分析技术工具， 用于大规模生产治疗药物的生物反应器中宿主细胞代谢的测量 病毒载体一种测量细胞内自发荧光的新型代谢细胞术传感器探针 代谢物将用于实时评估细胞水平的氧化还原代谢状态。一个创新 空间和时间限制的光谱方法用于有效区分荧光 非特异性光背景下的细胞内代谢物信号，实现高特异性 细胞生理学的测量。在第一阶段计划中，一个基于光纤的荧光原型 将制造和评估细胞仪探针系统，证明实时的能力， 用于病毒载体生产的生物反应器操作期间的代谢测量。技术成熟和 将在使用各种培养生物的其他生物反应器中进行应用示范 在第二阶段计划中。这项技术的成功开发将有助于重大的 对大规模生产病毒载体的生物工艺的理解和控制的改进 基因治疗产品。